Sarah Goldberg, MD, MPH

• Abhijit Patel
• Adebowale Adeniran
• Alfred Lee
• Anna Wurtz
• Anne Chiang
• Annette Komlo
• Benjamin Y. Lu
• Cary Gross
• Curtis Jamison Perry
• Daniel Boffa
• Daniel Zelterman
• David Rimm
• Edward Kaftan
• Fangyong Li
• Frederick Wilson
• Guoping Cai
• Harriet Kluger
• Heather Gerrish
• Henry S. Park
• Jeffrey Townsend
• Jennifer Possick
• Justin D. Blasberg
• Katerina Politi
• Lynn D. Wilson
• Mariam Aboian
• Mark A Lemmon
• Nikolai Podoltsev
• Robert Homer
• Roy S. Herbst
• Sarah Weiss
• Thuy Tran
• Veronica Chiang
• Vikram Jairam
• Xuchen Zhang
• Yuko Tsutsui
• Zenta Walther

Carcinoma, Non-Small-Cell Lung; Immunotherapy; Lung; Medical Oncology; Thoracic Neoplasms

Biomarkers

• Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutationsvan Alderwerelt van Rosenburgh I, Lu D, Grant M, Stayrook S, Phadke M, Walther Z, Goldberg S, Politi K, Lemmon M, Ashtekar K, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations Nature Communications 2022, 13: 6791. PMID: 36357385, PMCID: PMC9649653, DOI: 10.1038/s41467-022-34398-z.
• Cancer of the LungMorgensztern D, Morgensztern D, Boffa D, Chen A, Chen A, Dhanasopon A, Goldberg S, Decker R, Devarakonda S, Devarakonda S, Ko J, Ko J, Soto L, Soto L, Waqar S, Waqar S, Wistuba I, Wistuba I, Herbst R. Cancer of the Lung 2022, 1-29. DOI: 10.1002/9781119000822.hfcm085.pub2.
• EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung CancerStockhammer P, Grant M, Wurtz A, Foggetti G, Chung S, Li F, Gettinger S, Politi K, Goldberg S. EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer Journal Of Thoracic Oncology 2022, 17: s462-s463. DOI: 10.1016/j.jtho.2022.07.808.
• EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung CancerSpira A, Spigel D, Camidge R, de Langen A, Kim T, Goto K, Elamin Y, Shum E, Reckamp K, Rotow J, Goldberg S, Gadgeel S, Leal T, Albayya F, Fitzpatrick S, Louie-Gao M, Parepally J, Zalutskaya A, Yu H. EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Journal Of Thoracic Oncology 2022, 17: s406. DOI: 10.1016/j.jtho.2022.07.701.
• OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLCLi B, Falchook G, Durm G, Burns T, Skoulidis F, Ramalingam S, Spira A, Bestvina C, Goldberg S, Veluswamy R, Iams W, Chiappori A, Lemech C, Meloni A, Ebiana V, Dai T, Gauto D, Varrieur T, Snyder W, Govindan R. OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC Journal Of Thoracic Oncology 2022, 17: s10-s11. DOI: 10.1016/j.jtho.2022.07.025.
• P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)Barlesi F, Goldberg S, Mann H, Gopinathan A, Newton M, Aggarwal C. P1.10-01 Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9) Journal Of Thoracic Oncology 2022, 17: s107. DOI: 10.1016/j.jtho.2022.07.179.
• 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinibDe Langen J, Cho B, Piotrowska Z, Le X, Goldberg S, Goldman J, Okamoto I, Hewson N, Maidment J, Tang K, Veney N, Cosaert J, Lau J, Dressman M, Ambrose H, Riess J, Yu H. 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib Annals Of Oncology 2022, 33: s1091-s1092. DOI: 10.1016/j.annonc.2022.07.1311.
• Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD studyHartmaier R, Markovets A, Cho B, de Langen A, Goldberg S, Goldman J, Le X, Okamoto I, Riess J, Cosaert J, Yu H, Piotrowska Z. Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study Cancer Research 2022, 82: lb078-lb078. DOI: 10.1158/1538-7445.am2022-lb078.
• Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.Grant M, Aredo J, Starrett J, Wurtz A, Piotrowska Z, Piper-Vallillo A, Yu H, Falcon C, Patil T, Nguyen C, Aggarwal C, Scholes D, Li F, Phadke M, Neal J, Walther Z, Politi K, Goldberg S. Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. Journal Of Clinical Oncology 2022, 40: e21112-e21112. DOI: 10.1200/jco.2022.40.16_suppl.e21112.
• A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.Chiang A, Austin M, Stewart T, Arammash M, Bhatt S, Gettinger S, Goldberg S, Wilson F, Newton B, Cohenuram M, Sabbath K, Talsania A, Russo A, Herbst R, Schalper K. A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy. Journal Of Clinical Oncology 2022, 40: 8583-8583. DOI: 10.1200/jco.2022.40.16_suppl.8583.
• A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).Skoulidis F, Redman M, Suga J, Al Baghdadi T, Villano J, Goldberg S, Villaruz L, Minichiello K, Gandara D, Herbst R, Kelly K. A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). Journal Of Clinical Oncology 2022, 40: 9060-9060. DOI: 10.1200/jco.2022.40.16_suppl.9060.
• A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR -mutant non–small cell lung cancer (NSCLC).Spira A, Spigel D, Camidge D, De Langen A, Kim T, Goto K, Elamin Y, Shum E, Reckamp K, Rotow J, Goldberg S, Gadgeel S, Leal T, Albayya F, Fitzpatrick S, Louie-Gao M, Parepally J, Zalutskaya A, Yu H. A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR -mutant non–small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2022, 40: tps9142-tps9142. DOI: 10.1200/jco.2022.40.16_suppl.tps9142.
• 162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumorsEven C, Goldberg S, Siu L, Planchard D, Hwang M, Chen C, He J, Song X, Zhou D, Doake R, Krug L, Peters S. 162P Population pharmacokinetic modeling of tremelimumab in patients (pts) with advanced solid tumors Annals Of Oncology 2021, 32: s1451-s1452. DOI: 10.1016/j.annonc.2021.10.181.
• Implementing a Full Time Equivalent-Supported Hematology/Oncology Fellowship Core Faculty Program May Improve Faculty Engagement in Education, Mentorship, and RecruitmentChristian J, Gilkes L, Goldberg S, Hurwitz M, Podoltsev N, Lee A. Implementing a Full Time Equivalent-Supported Hematology/Oncology Fellowship Core Faculty Program May Improve Faculty Engagement in Education, Mentorship, and Recruitment Blood 2021, 138: 2974-2974. DOI: 10.1182/blood-2021-154326.
• Management of Brain MetastasesCollier E, Chiang V, Goldberg S. Management of Brain Metastases 2021, 115-137. DOI: 10.1007/978-3-030-74028-3_6.
• 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinibYu H, Ambrose H, Baik C, Cho B, Cocco E, Goldberg S, Goldman J, Kraljevic S, de Langen A, Okamoto I, Piotrowska Z, Pluta M, Powar S, Aransay N, Riess J, Le X. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib Annals Of Oncology 2021, 32: s978-s979. DOI: 10.1016/j.annonc.2021.08.1844.
• Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisSandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.
• Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.Jairam V, Pasha S, Pasha S, Soulos P, Soulos P, Goldberg S, Yu J, Yu J, Decker R, Gross C, Park H. Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer. Journal Of Clinical Oncology 2021, 39: e20550-e20550. DOI: 10.1200/jco.2021.39.15_suppl.e20550.
• Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).Hong D, Strickler J, Fakih M, Falchook G, Li B, Durm G, Burns T, Ramalingam S, Goldberg S, Frank R, Marrone K, Shu C, Gandara D, Soman N, Henary H, Govindan R. Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101). Journal Of Clinical Oncology 2021, 39: tps2669-tps2669. DOI: 10.1200/jco.2021.39.15_suppl.tps2669.
• P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line OsimertinibCho B, Piotrowska Z, Le X, Goldberg S, Goldman J, De Langen A, Okamoto I, Smith P, Mensi I, Maidment J, Hartmaier R, Li M, Doughton G, Patel G, Pease J, Szekeres P, Riess J, Yu H. P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib Journal Of Thoracic Oncology 2021, 16: s598. DOI: 10.1016/j.jtho.2021.01.1084.
• Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)Felip E, Lim F, Johnson M, O'Brien M, Barlesi F, Mazieres J, Solomon B, Moreno V, Boni V, Swalduz A, Goldberg S, Keam B, Allen S, Helms H, Shemesh C, Pintoffl J, Al-Sakaff N, Bailey L, Sayyed P, Cho B. Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) Annals Of Oncology 2020, 31: s850. DOI: 10.1016/j.annonc.2020.08.1629.
• Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.Mack P, Redman M, Moon J, Goldberg S, Herbst R, Melnick M, Walther Z, Hirsch F, Politi K, Kelly K, Gandara D. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal Of Clinical Oncology 2020, 38: 9532-9532. DOI: 10.1200/jco.2020.38.15_suppl.9532.
• Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.Pathak R, Lopes G, Yu H, Ji W, Aryal M, Frumento K, Wallis C, Klaassen Z, Park H, Goldberg S. Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis. Journal Of Clinical Oncology 2020, 38: 9552-9552. DOI: 10.1200/jco.2020.38.15_suppl.9552.
• Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR MutationsStarrett J, Guernet A, Cuomo M, Poels K, K. Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.00612.
• B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR MutationsStarrett J, Guernet A, Cuomo M, Poels K, Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations Journal Of Thoracic Oncology 2020, 15: s36. DOI: 10.1016/j.jtho.2019.12.097.
• RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTSKluger H, Forsyth P, Khushalani N, Eroglu Z, Sznol M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS Neuro-Oncology 2019, 21: vi220-vi220. PMCID: PMC6847787, DOI: 10.1093/neuonc/noz175.919.
• P2.17-07 Role of Adjuvant Chemotherapy After Sublobar Resection in Stage I NSCLCPathak R, Goldberg S, Hoag J, Monsalve A, Resio B, Papageorge M, Boffa D. P2.17-07 Role of Adjuvant Chemotherapy After Sublobar Resection in Stage I NSCLC Journal Of Thoracic Oncology 2019, 14: s886. DOI: 10.1016/j.jtho.2019.08.1918.
• P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib TherapyYu H, Goldberg S, Le X, Piotrowska Z, Smith P, Mensi I, Kirova B, Chmielecki J, Li-Sucholeicki X, Szekeres P, Doughton G, Patel G, Jewsbury P, Riess J. P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy Journal Of Thoracic Oncology 2019, 14: s647. DOI: 10.1016/j.jtho.2019.08.1366.
• Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)Campbell A, Cai W, Burkhardt D, Gettinger S, Goldberg S, Amodio M, Kaech S, Krishnaswamy S, Decker R. Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s36-s37. DOI: 10.1016/j.ijrobp.2019.06.453.
• Cerebrospinal Fluid Biomarkers of Brain MetastasisCheok S, Arnal-Estape A, Narayan A, Zakaria M, Goldberg S, Patel A, Nguyen D, Chiang V. Cerebrospinal Fluid Biomarkers of Brain Metastasis Neurosurgery 2019, 66: 310-631. DOI: 10.1093/neuros/nyz310_631.
• Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.Peters S, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, Baas P, Dols M, Smolin A, Vicente D, Moiseyenko V, Antonia S, Nakagawa K, Goldberg S, Kim E, Raja R, Brohawn P, Clemett D, Thiyagarajah P, Scheuring U, Liu F, Rizvi N. Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. 2019, ct074-ct074. DOI: 10.1158/1538-7445.sabcs18-ct074.
• Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.Peters S, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, Baas P, Dols M, Smolin A, Vicente D, Moiseyenko V, Antonia S, Nakagawa K, Goldberg S, Kim E, Raja R, Brohawn P, Clemett D, Thiyagarajah P, Scheuring U, Liu F, Rizvi N. Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. Cancer Research 2019, 79: ct074-ct074. DOI: 10.1158/1538-7445.am2019-ct074.
• Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.Pathak R, Hoag J, Goldberg S, Monsalve A, Resio B, Boffa D. Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. Journal Of Clinical Oncology 2019, 37: 8519-8519. DOI: 10.1200/jco.2019.37.15_suppl.8519.
• Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.Lu B, Gupta R, Gupta R, Stewart T, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. Journal Of Clinical Oncology 2019, 37: 2066-2066. DOI: 10.1200/jco.2019.37.15_suppl.2066.
• Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.Rizvi N, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, van den Heuvel M, Dols M, Vicente D, Smolin A, Moiseyenko V, Antonia S, Nakagawa K, Goldberg S, Kim E, Walker J, Raja R, Liu F, Scheuring U, Peters S. Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. Journal Of Clinical Oncology 2019, 37: 9016-9016. DOI: 10.1200/jco.2019.37.15_suppl.9016.
• 105O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM studyAhn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok T. 105O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study Annals Of Oncology 2019, 30: ii48. DOI: 10.1093/annonc/mdz063.003.
• 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer DatabaseUhlig J, Uhlig J, Dendy M, Goldberg S, Chiang A, Blasberg J, Kim H, Kim H. 03:00 PM Abstract No. 278 Thermal ablation versus stereotactic radiation therapy for stage 4 lung cancer: contemporary trends and outcomes from the National Cancer Database Journal Of Vascular And Interventional Radiology 2019, 30: s124-s125. DOI: 10.1016/j.jvir.2018.12.342.
• Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or MelanomaCampbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s18-s19. DOI: 10.1016/j.ijrobp.2018.06.134.
• 492O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLCAhn M, Chiu C, Cheng Y, Han J, Goldberg S, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok T. 492O Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC Annals Of Oncology 2018, 29: ix151-ix152. DOI: 10.1093/annonc/mdy425.003.
• OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L, Chen E, Mashru S, Gettinger S, Melnick M, Miao J, Moon J, Kelly K, Gandara D. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403 Journal Of Thoracic Oncology 2018, 13: s343-s344. DOI: 10.1016/j.jtho.2018.08.290.
• P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLCRizvi N, Shu C, Goldberg S, Papadimitrakopoulou V, Camidge D, Patel S, Marrone K, Kim S, Kim D, Hsieh H, Mueller N, Kumar R, Englert J, Park K. P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC Journal Of Thoracic Oncology 2018, 13: s930-s931. DOI: 10.1016/j.jtho.2018.08.1730.
• Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
• Differential outcomes in patients with uncommon EGFR exon 19 mutations.Stewart T, Truini A, DeVeaux M, Zelterman D, Walther Z, Wurtz A, Gettinger S, Politi K, Goldberg S. Differential outcomes in patients with uncommon EGFR exon 19 mutations. Journal Of Clinical Oncology 2018, 36: 9056-9056. DOI: 10.1200/jco.2018.36.15_suppl.9056.
• Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger H. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Journal Of Clinical Oncology 2018, 36: 2009-2009. DOI: 10.1200/jco.2018.36.15_suppl.2009.
• Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma.Campbell A, Herbst R, Gettinger S, Goldberg S, Kluger H, Chiang A, Lilenbaum R, Schalper K, Sowell R, Kaech S, Decker R. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma. Journal Of Clinical Oncology 2018, 36: 9099-9099. DOI: 10.1200/jco.2018.36.15_suppl.9099.
• Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy.Tran T, Jilaveanu L, Mahajan A, Goldberg S, Nguyen D, Chiang V, Kluger H. Perilesional edema and blood vessel characteristics in brain metastases and implications for treatment with immune therapy. Journal Of Clinical Oncology 2018, 36: 9572-9572. DOI: 10.1200/jco.2018.36.15_suppl.9572.
• PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases.Lu B, Gupta R, Gupta R, Ribeiro M, Ribeiro M, Stewart T, Stewart T, Chiang V, Contessa J, Adeniran A, Kluger H, Jilaveanu L, Schalper K, Goldberg S. PD-L1 expression and tumor-infiltrating lymphocytes in lung cancer brain metastases. Journal Of Clinical Oncology 2018, 36: e24116-e24116. DOI: 10.1200/jco.2018.36.15_suppl.e24116.
• Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.Garon E, Spira A, Goldberg S, Chaft J, Papadimitrakopoulou V, Antonia S, Brahmer J, Camidge D, Powderly J, Wozniak A, Felip E, Gao G, Englert J, Awad M. Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients. Journal Of Clinical Oncology 2018, 36: 9041-9041. DOI: 10.1200/jco.2018.36.15_suppl.9041.
• MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).Johnson M, Solomon B, Awad M, Cho B, Gainor J, Goldberg S, Keam B, Lee D, Huang C, Helms H, Barak H, Fasso M, Bleul C, Cha E, Rizvi N. MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: tps9105-tps9105. DOI: 10.1200/jco.2018.36.15_suppl.tps9105.
• 3:10 PM Abstract No. 44 Thermal ablation and stereotactic radiation therapy for stage I NSCLC: contemporary trends and outcomes from the National Cancer DatabaseUhlig J, Gettinger S, Goldberg S, Kim H. 3:10 PM Abstract No. 44 Thermal ablation and stereotactic radiation therapy for stage I NSCLC: contemporary trends and outcomes from the National Cancer Database Journal Of Vascular And Interventional Radiology 2018, 29: s23. DOI: 10.1016/j.jvir.2018.01.053.
• P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without CetuximabMack P, Miao J, Banks K, Burich R, Politi K, Raymond V, Dix D, Lanman R, Moon J, Melnick M, Truini A, Redman M, Goldberg S, Gandara D, Kelly K. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab Journal Of Thoracic Oncology 2017, 12: s2219. DOI: 10.1016/j.jtho.2017.09.1487.
• 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNAGoldberg S, Narayan A, Narayan A, Kole A, Kole A, Decker R, Teysir J, Teysir J, Carriero N, Lee A, Nemati R, Nemati R, Nath S, Nath S, Mane S, Deng Y, Sukumar N, Sukumar N, Zelterman D, Boffa D, Politi K, Gettinger S, Wilson L, Herbst R, Patel A. 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA Annals Of Oncology 2017, 28: v478. DOI: 10.1093/annonc/mdx380.043.
• 1358P First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKIHusain H, Martins R, Goldberg S, Senico P, Ma W, Masters J, Pathan N, Kim D, Socinski M, Goldberg Z, Cho B. 1358P First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI Annals Of Oncology 2017, 28: v485-v486. DOI: 10.1093/annonc/mdx380.060.
• Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).Henick B, Goldberg S, Narayan A, Rossi C, Rodney S, Kole A, Politi K, Gettinger S, Herbst R, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: e20652-e20652. DOI: 10.1200/jco.2017.35.15_suppl.e20652.
• Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.Thress K, Markovets A, Barrett J, Chmielecki J, Goldberg S, Shepherd F, Vowler S, Oxnard G. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal Of Clinical Oncology 2017, 35: 9018-9018. DOI: 10.1200/jco.2017.35.15_suppl.9018.
• MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC) Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
• MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung AdenocarcinomasHastings K, Hastings K, Choi J, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Oliva I, Zhao Z, Zhao Z, Gaffney S, Gaffney S, Iamarino A, Iamarino A, Zhao S, Zhao S, Bi M, Bi M, Goldberg S, Chiang A, Liu Z, Liu Z, Townsend J, Schlessinger J, Lifton R, Herbst R, Gettinger S, Politi K. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas Journal Of Thoracic Oncology 2017, 12: s435. DOI: 10.1016/j.jtho.2016.11.507.
• P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
• P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
• P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Topic: EGFR ClinicalGoldberg S, Moon J, Lilenbaum R, Politi K, Melnick M, Stinchcombe T, Horn L, Chen E, Miao J, Redman M, Kelly K, Gandara D. P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Topic: EGFR Clinical Journal Of Thoracic Oncology 2017, 12: s1220-s1221. DOI: 10.1016/j.jtho.2016.11.1719.
• P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC Topic: EGFR BiomarkersHusain H, Martins R, Goldberg S, Senico P, Ma W, Masters J, Pathan N, Kim D, Socinski M, Goldberg Z, Cho B. P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC Topic: EGFR Biomarkers Journal Of Thoracic Oncology 2017, 12: s1185. DOI: 10.1016/j.jtho.2016.11.1668.
• Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.
• HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
• 191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLCPeters S, Antonia S, Goldberg S, Heymach J, Kim E, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi N. 191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC Journal Of Thoracic Oncology 2016, 11: s139-s140. DOI: 10.1016/s1556-0864(16)30300-8.
• 418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLCRizvi N, Balmanoukian A, Goldberg S, Chaft J, Sanborn R, Rebelatto M, Narwal R, Robbins P, Gu Y, Karakunnel J, Antonia S. 418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC Annals Of Oncology 2015, 26: ix125. DOI: 10.1093/annonc/mdv532.02.
• Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTICRizvi N, Barlesi F, Brahmer J, Felip E, Forde P, Garassino M, Goldberg S, Vansteenkiste J, Jarkowski A, McIntosh S, Zhao L, Antonia S. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC Journal For ImmunoTherapy Of Cancer 2015, 3: p171. PMCID: PMC4646121, DOI: 10.1186/2051-1426-3-s2-p171.
• Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 statusRizvi N, Chaft J, Balmanoukian A, Goldberg S, Sanborn R, Steele K, Rebelatto M, Gu Y, Karakunnel J, Antonia S. Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status Journal For ImmunoTherapy Of Cancer 2015, 3: p193. PMCID: PMC4649434, DOI: 10.1186/2051-1426-3-s2-p193.
• 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLCGoldberg S, Balmanoukian A, Chaft J, Rizvi N, Sanborn R, Rebelatto M, Narwal R, Robbins P, Gu Y, Karakunnel J, Antonia S. 3086 A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC European Journal Of Cancer 2015, 51: s627. DOI: 10.1016/s0959-8049(16)31727-0.
• Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris A, Vortmeyer A, Jilaveanu L, Speaker S, Madura M, Rowen E, Gerrish H, Knapp-Perry E, Yao X, Chiang V, Kluger H. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 8035-8035. DOI: 10.1200/jco.2015.33.15_suppl.8035.
• Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.Kluger H, Goldberg S, Sznol M, Tsiouris J, Vortmeyer A, Jilaveanu L, Ralabate A, Rivera A, Burke M, Hegbe U, Cohen J, Yao X, Speaker S, Madura M, Knapp-Perry E, Mahajan A, Chiang V. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. Journal Of Clinical Oncology 2015, 33: 9009-9009. DOI: 10.1200/jco.2015.33.15_suppl.9009.
• Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.Antonia S, Goldberg S, Balmanoukian A, Sanborn R, Steele K, Narwal R, Robbins P, Gu Y, Karakunnel J, Rizvi N. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. Journal Of Clinical Oncology 2015, 33: 3014-3014. DOI: 10.1200/jco.2015.33.15_suppl.3014.
• Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)Brahmer J, Balmanoukian A, Goldberg S, Ou S, Blake-Haskins A, Karakunnel J, Stockman P, Rizvi N, Antonia S. Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) Journal For ImmunoTherapy Of Cancer 2014, 2: p179. PMCID: PMC4288573, DOI: 10.1186/2051-1426-2-s3-p179.
• Cost Effectiveness Analysis of Stereotactic Body Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer Outcomes/Health Services ResearchLester-Coll N, Goldberg S, Yu J, Decker R. Cost Effectiveness Analysis of Stereotactic Body Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer Outcomes/Health Services Research International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s58. DOI: 10.1016/j.ijrobp.2014.08.271.
• 1327P A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc)Antonia S, Goldberg S, Balmanoukian A, Narwal R, Robbins P, D'Angelo G, Blake-Haskins A, Karakunnel J, Rizvi N. 1327P A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Medi4736, an Anti-Programmed Cell Death-Ligand 1(Pd-L1) Antibody, in Combination with Tremelimumab in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc) Annals Of Oncology 2014, 25: iv466. DOI: 10.1093/annonc/mdu349.106.
• Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma.Goldberg S, Narayan A, Narayan A, Carriero N, Nemati R, Nemati R, Bommakanti A, Bommakanti A, Wurtz A, Boffa D, Decker R, Herbst R, Juergensmeier J, Juergensmeier J, Politi K, Gettinger S, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 8093-8093. DOI: 10.1200/jco.2014.32.15_suppl.8093.
• Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).McLaughlin J, Schalper K, Carvajal-Hausdorf D, Velcheti V, Haack H, Silver M, Goldberg S, Herbst R, Rimm D. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8064-8064. DOI: 10.1200/jco.2014.32.15_suppl.8064.
• A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).Neal J, Wakelee H, Feliciano J, Goldberg S, Morgensztern D, Das M, Heist R, Lennes I, Muzikansky A, Edelman M, Gettinger S, Sequist L. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8088-8088. DOI: 10.1200/jco.2014.32.15_suppl.8088.
• A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer.Pinder M, Rizvi N, Goldberg S, Balmanoukian A, Narwal R, Robbins P, D'Angelo G, Blake-Haskins A, Karakunnel J, Antonia S. A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in subjects with advanced non–small cell lung cancer. Journal Of Clinical Oncology 2014, 32: e19137-e19137. DOI: 10.1200/jco.2014.32.15_suppl.e19137.
• Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR -mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.Heon S, Nishino M, Goldberg S, Porter J, Sequist L, Jackman D, Johnson B. Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR -mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. Journal Of Clinical Oncology 2012, 30: 7525-7525. DOI: 10.1200/jco.2012.30.15_suppl.7525.
• Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).Goldberg S, Oxnard G, Digumarthy S, Muzikansky A, Jackman D, Lennes I, Sequist L. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Journal Of Clinical Oncology 2012, 30: 7524-7524. DOI: 10.1200/jco.2012.30.15_suppl.7524.